| 产品名称 | AZD 2858 hydrochloride |
| 产品货号 | Axon 2194 CAS [486424-21-9] MF C21H23N7O3S.HClMW 489.98 Purity: 98% Soluble in water and DMSO Description Potent and highly selective Glycogen Synthase Kinase-3β (GSK-3β; Ki value 4.9 nM) inhibitor for Alzheimer’s disease with good BBB permeability in a bovine endothelial cell assay. AZD 2858 inhibits GSK-3β-mediated tau phosphorylation (IC50 value 76 nM) in vitro, and shows a good overall selectivity versus a panel of 26 kinases and >100 fold selectivity over CDK2 (Ki value 540 nM).In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK-3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis. References Certificates Categories Extra info S. Berg et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J. Med. Chem. 2012, 55, 9107-9119. R. Marsell et al. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone. 2012, 50, 619-627. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS Diabetes & Metabolism Immunology Pain & Inflammation Stem Cell GSK-3 Wnt-β-Catenin PI3K-Akt-mTOR EC 2.7.11.26 Potent and highly selective Glycogen Synthase Kinase-3β inhibitor Chemical name 4-amino-4'-(4-methylpiperazin-1-ylsulfonyl)-N-(pyridin-3-yl)biphenyl-3-carboxamide hydrocholride Parent CAS No. [486424-20-8] Order Size Unit Price Stock 5 mg €95.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
AZD 2858 hydrochlorideAxon 2194 CAS [486424-21-9] MF C21H23N7O3S.HCl
Description
Potent and highly selective Glycogen Synthase Kinase-3β (GSK-3β; Ki value 4.9 nM) inhibitor for Alzheimer’s disease with good BBB permeability in a bovine endothelial cell assay. AZD 2858 inhibits GSK-3β-mediated tau phosphorylation (IC50 value 76 nM) in vitro, and shows a good overall selectivity versus a panel of 26 kinases and >100 fold selectivity over CDK2 (Ki value 540 nM).In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK-3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis.
Potent and highly selective Glycogen Synthase Kinase-3β inhibitor
Chemical name4-amino-4'-(4-methylpiperazin-1-ylsulfonyl)-N-(pyridin-3-yl)biphenyl-3-carboxamide hydrocholride Parent CAS No.[486424-20-8] |
| 产品资料 |
